Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66.
A pilot safety and immunogenicity trial of the malaria vaccine SPf66 was undertaken in The Gambia in 1993. One hundred and fifty infants aged 6-11 months were immunized with either 0.5 mg or 1.0 mg of SPf66 produced either in Colombia or in the USA or with a control vaccine. Children who received SPf66 experienced more clinical attacks of malaria than did children in the control group during the first period of surveillance and the difference in incidence between children who had received high dose Colombian vaccine and the control children was statistically significant at the 5% level. During the 1995 malaria transmission season, 127 children from the original cohort of 150 were observed. During 18 weeks of intensive surveillance, the incidence of clinical malaria was again higher among children who had received SPf66 than among children who had received inactivated polio vaccine (6.23 vs 4.89 clinical attacks per 1000 days at risk), the effect being most marked among children who were in the high dose groups, but differences between groups were now no longer statistically significant.
Bojang
K A
KA
Medical Research Council Laboratories, Fajara, The Gambia.
Obaro
S K
SK
Leach
A
A
D'Alessandro
U
U
Bennett
S
S
Metzger
W
W
Ballou
W R
WR
Targett
G A
GA
Greenwood
B M
BM
D002648:Child; D003257:Consumer Product Safety; D005500:Follow-Up Studies; D005714:Gambia; D006801:Humans; D007231:Infant, Newborn; D008288:Malaria / Q000276:immunology / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000276:immunology*; D010865:Pilot Projects; D015800:Protozoan Proteins / Q000276:immunology*; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic / Q000276:immunology*
D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; D014614:Vaccines, Synthetic